Jiang Tao, Zhou Caicun
Shanghai Pulmonary Hospital, Shanghai 200433, China.
Zhongguo Fei Ai Za Zhi. 2015 Apr;18(4):240-4. doi: 10.3779/j.issn.1009-3419.2015.04.09.
Molecular targeted therapy has become more and more important in the treatment of non-small cell lung cancer (NSCLC). HGF/c-MET plays the pivotal role in the growth, development and tolerance to epidermal growth factor receptor tyrosine kinase inhibitor of NSCLC. Moreover it has become another heat point in the molecular targeted therapy of NSCLC. c-MET amplification or high expression was deemed to another significant gene modification beyond EGFR and ALK. In the preclinical studies, HGF/c-MET inhibitors have showed the promising anti-tumor effect. Recently, some phase II/III clinical trials have proved that these inhibitors could improve the survival of patients with NSCLC. Hence we performed this review to elaborate the research progress of c-MET inhibitor in the treatment of NSCLC.
分子靶向治疗在非小细胞肺癌（NSCLC）的治疗中变得越来越重要。HGF/c-MET在NSCLC的生长、发展以及对表皮生长因子受体酪氨酸激酶抑制剂的耐受性中起关键作用。此外，它已成为NSCLC分子靶向治疗的另一个热点。c-MET扩增或高表达被认为是除EGFR和ALK之外的另一种重要基因改变。在临床前研究中，HGF/c-MET抑制剂已显示出有前景的抗肿瘤作用。最近，一些II/III期临床试验证明这些抑制剂可以改善NSCLC患者的生存率。因此，我们进行了本综述以阐述c-MET抑制剂在NSCLC治疗中的研究进展。
